Jacob Kimmel

One stat on why I think that's true, something like a third of all Medicare costs are spent in the final year of life, which is shocking when you realize that the average person on Medicare is, I don't know the exact number, but probably a decade plus covered by it.

And so there's an incredible concentration of the actual expenses once someone is already terribly sick.

So helping prevent you from ever having to access the intensive healthcare system, meaning something like an inpatient hospital visit, if you can prevent even just a couple of those visits over a long period of someone's life with a medicine like an increment medic, like a reprogramming medicine that keeps your liver, your immune system younger, I think on net that actually starts to drive healthcare spend down because you're sort of shifting some of that burden from the administration system to the pharmaceutical system.

And the pharmaceutical system is the only piece of healthcare where technology has made us more efficient.

Yeah.

As drugs go generic, actually the cost of administering a given unit of healthcare is going down.

And the grand social contract is that they eventually go generic.

That's the way our current IP system works.

So I think, you know, if you were to get the question of like, when would you like to be born as a patient?

You always want to be born as close to today as possible because for a given unit in terms of pharmaceuticals, for a given dollar unit of expense, you can access more pharmaceutical technology today than has ever been possible in history.

even as healthcare costs everywhere else in the system have shot up.

And so pharmaceuticals are the one place where because of the mechanism of things going generic and the fact that our old medicines continue to work and persist over time, you're actually able to get more benefit per dollar.

Yeah.

So I'll just correct one thing to make sure I'm not overstating.

We have way more data for, in particular, the limited sub-problem we're tackling, which is overexpressing TFs in combinations.

I think we have way more data than anyone on full stop there.

But even more specifically, I feel very, very confident we have more data than anyone looking at trying to reprogram a cell's age.

And so that's where we're way larger than the rest of the world.

When we think about just general single cell perturbation data, various flavors, then I think there are other groups which have very large data sets as well.

We're still differentiated because we do everything in human cells with the right number of chromosomes, whereas it's very common to do things in like cancer cell lines, which have 200 chromosomes.